| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OVCA2 |
| Uniprot No | Q8WZ82 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-227aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMAAQRP LRVLCLAGFR QSERGFREKT GALRKALRGR AELVCLSGPH PVPDPPGPEG ARSDFGSCPP EEQPRGWWFS EQEADVFSAL EEPAVCRGLE ESLGMVAQAL NRLGPFDGLL GFSQGAALAA LVCALGQAGD PRFPLPRFIL LVSGFCPRGI GFKESILQRP LSLPSLHVFG DTDKVIPSQE SVQLASQFPG AITLTHSGGH FIPAAAPQRQ AYLKFLDQFA E |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OVCA2重组蛋白的3篇参考文献示例，涵盖不同研究方向：
1. **标题**：*Expression and Purification of Recombinant OVCA2 Protein in Escherichia coli*
**作者**：Chen L, Wang Y, et al.
**摘要**：该研究成功构建了OVCA2的重组表达载体，并利用大肠杆菌系统实现了高效表达。通过亲和层析技术纯化获得高纯度蛋白，并验证了其抗原性，为后续抗体开发及功能研究奠定了基础。
2. **标题**：*Functional Characterization of OVCA2 Recombinant Protein in Ovarian Cancer Cell Apoptosis*
**作者**：Zhang R, Liu X, et al.
**摘要**：研究发现，体外表达的OVCA2重组蛋白能显著诱导卵巢癌细胞凋亡，并通过激活caspase-3通路抑制肿瘤生长，提示其作为潜在肿瘤抑制因子的作用机制。
3. **标题**：*Structural Insights into OVCA2 Recombinant Protein by Circular Dichroism Spectroscopy*
**作者**：Kim S, Patel A, et al.
**摘要**：利用圆二色光谱分析了OVCA2重组蛋白的二级结构，揭示其含有高比例α-螺旋结构域，并探讨了特定结构域突变对蛋白稳定性的影响，为功能关联研究提供结构依据。
(注：以上文献为示例性内容，实际研究中请通过学术数据库核实具体文献。)
OVCA2 (Ovarian Cancer-associated gene 2) is a protein-coding gene implicated in tumor suppression, particularly in ovarian cancer. Initially identified through genomic studies of ovarian carcinomas, OVCA2 is located on chromosome 17q21.31. a region frequently associated with loss of heterozygosity (LOH) in ovarian and breast cancers. The gene is part of a tumor suppressor network, with its expression often downregulated or silenced in cancer tissues due to epigenetic modifications, such as promoter hypermethylation, or genetic deletions. Functionally, OVCA2 is believed to regulate cell cycle progression and apoptosis, though its precise molecular mechanisms remain under investigation. Studies suggest it interacts with pathways involving p53 and other tumor suppressors, influencing cellular responses to DNA damage and stress.
Recombinant OVCA2 protein is produced using biotechnological systems (e.g., E. coli or mammalian expression systems) to enable functional studies. Researchers utilize this protein to explore its role in cancer biology, including its potential to inhibit proliferation, induce cell cycle arrest, or sensitize cancer cells to chemotherapy. Additionally, recombinant OVCA2 serves as an antigen for antibody development, aiding in diagnostic assays to detect ovarian cancer biomarkers or monitor disease progression. Despite its promising associations, clinical applications remain exploratory, with ongoing studies aiming to validate its utility as a prognostic marker or therapeutic target. The protein’s study contributes to broader efforts in understanding ovarian cancer pathogenesis and developing targeted therapies for this malignancy, which often presents with late-stage diagnosis and limited treatment options.
×
